Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Eli Lilly and Company
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- EXPEDITION 3
- status
- TERMINATED
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 2129
- sponsor
- Eli Lilly and Company
- conditions
- Alzheimer's Disease
- interventions
- DRUG: Solanezumab; DRUG: Placebo
- start date
- 2013-07-01
- primary completion date
- 2016-10-01
- has results
- true
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT01900665
- Published
- Jul 16, 2013
- Updated
- Oct 9, 2019
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT01900665
- Categories
- Alzheimer's Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials